Kathryn Ann Morton

Prof. Kathryn Ann Morton

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
MRMatthew T. Rondina
Matthew T. Rondina
ULUyen T. Lam
Uyen T. Lam
RPRobert C. Pendleton
Robert C. Pendleton
LKLarry W. Kraiss
Larry W. Kraiss
NWNathan Wanner
Nathan Wanner
KMKathryn Ann Morton
Kathryn Ann Morton
Purpose 18F-FDG PET has been used for vascular disease, but its role in deep vein thrombosis (DVT) remains prospectively unexplored. Patients and Methods Whole-body 18F-FDG PET/CT scans were performed in patients 1 to 10 weeks after onset of symptomatic DVT (n = 12) and in control subjects without DVT (n = 24). The metabolic activity (SUVmax) of thrombosed and contralateral nonthrombosed vein segments was determined. The sensitivity and specificity of 18F-FDG PET/CT for the diagnosis of DVT were determined by receiver operating characteristic curve analyses. In 2 patients with DVT, changes in the metabolic activity of thrombosed vein segments in serial 18F-FDG PET scans. Results The metabolic activity in thrombosed veins [SUVmax, 2.41 (0.75)] was visually appreciable and significantly higher than in nonthrombosed veins in either the contralateral extremity of patients with DVT [SUVmax, 1.09 (0.25), P = 0.007] or control subjects [1.21 (0.22), P < 0.001]. The area under the receiver operating characteristic curve for SUVmax was 0.9773 (P < 0.001), indicating excellent accuracy. An SUVmax threshold of greater than 1.645 was 87.5% sensitive and 100% specific for DVT. Metabolic activity in thrombosed veins correlated significantly with time from DVT symptom onset (decrease in SUVmax of 0.02/d, P < 0.05). Best-fit-line analyses suggested that approximately 84 to 91 days after acute DVT, the maximum metabolic activity of thrombosed veins would return to normal levels. Conclusions 18F-FDG PET/CT is accurate for detecting acute symptomatic, proximal DVT. Metabolic activity in thrombosed veins decreases with time, suggesting that 18F-FDG PET may be helpful in assessing the age of the clot.

6 August 2008 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
RRR. S. Rodrigues
R. S. Rodrigues
PMP. R. Miller
P. R. Miller
FBFernando Bozza
Fernando Bozza
EMEdson Santos Marchiori
Edson Santos Marchiori
GZG. A. Zimmerman
G. A. Zimmerman
KMKathryn Ann Morton
Kathryn Ann Morton

11 October 2021 in Tomography
Verified
Journal Article
Open access
PDF file
BKBhasker rao Koppula
Bhasker rao Koppula
KMKathryn Ann Morton
Kathryn Ann Morton
RARagheed Al-Dulaimi
Ragheed Al-Dulaimi
GFGabriel Fine
Gabriel Fine
NDNikolas M. Damme
Nikolas M. Damme
RBRichard K. J. Brown
Richard K. J. Brown
Dedicated multi-slice single-photon emission computed tomography/computed tomography (SPECT/CT) cameras have become widely available and are becoming a mainstay of clinical practice. The integration of SPECT and CT allow for precise anatomic location of scintigraphic findings. Fusion imaging with SPECT/CT can improve both sensitivity and specificity by reducing equivocal interpretation in comparison to planar scintigraphy or SPECT alone. This review article addresses the technique, basic science principles, and applications of integrated SPECT/CT in the evaluation of musculoskeletal pathology.

1 January 2018
Verified
Journal Article
Closed access
LWLi-Ming Wang
Li-Ming Wang
QWQi Wu
Qi Wu
RKRyan A. Kirk
Ryan A. Kirk
KHKevin P. Horn
Kevin P. Horn
ASAhmed H. Ebada Salem
Ahmed H. Ebada Salem
KMKathryn Ann Morton
Kathryn Ann Morton

31 August 2019 in GeroScience
Verified
Journal Article
Closed access
PDF file
RKRyan A. Kirk
Ryan A. Kirk
RKRaymond P. Kesner
Raymond P. Kesner
LWLi-Ming Wang
Li-Ming Wang
QWQi Wu
Qi Wu
RTRheal A. Towner
Rheal A. Towner
KMKathryn Ann Morton
Kathryn Ann Morton

3 September 2015 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
KHKevin P. Horn
Kevin P. Horn
JYJeffrey T. Yap
Jeffrey T. Yap
NANeeraj Agarwal
Neeraj Agarwal
KMKathryn Ann Morton
Kathryn Ann Morton
DKDan J. Kadrmas
Dan J. Kadrmas
JHJohn Hoffman
John Hoffman
Background: Metastatic renal cell carcinoma has a poor prognosis and an intrinsic resistance to standard treatment. Sunitinib is an oral receptor tyrosine kinase inhibitor that has been used as a first-line targeted therapy in metastatic renal cell carcinoma. While computed tomography (CT) is currently the gold standard for response assessment in oncological trials, numerous studies have shown that positron emission tomography (PET) imaging can provide information predictive of tumor response to treatment earlier than the typical interval for standard of care follow-up CT imaging. In this exploratory study we sought to characterize early tumor response in patients with metastatic renal cell carcinoma treated with continuous daily 37.5 mg sunitinib therapy. Methods: Twenty patients underwent dynamic acquisition positron emission tomography (PET) imaging using 18 F-fluorodeoxyglucose (FDG) and 18 F-fluorothymidine (FLT) at baseline and early in treatment (after 1, 2, 3 or 4 weeks) with 37.5 mg continuous daily dosing of sunitinib. Semi-quantitative analyses were performed to characterize the tumor metabolic (FDG) and proliferative (FLT) responses to treatment. Results: Proliferative responses were observed in 9/19 patients and occurred in 2 patients at one week (the earliest interval evaluated) after the initiation of therapy. A metabolic response was observed in 5/19 patients, however this was not observed until after two weeks of therapy were completed. Metabolic progression was observed in 2/19 patients and proliferative progression was observed in 1/19 patients. Baseline FDG-PET tumor maximum standardized uptake values correlated inversely with overall survival (p = 0.0036). Conversely, baseline 18 F-fluorothymidine PET imaging did not have prognostic value (p = 0.56) but showed a greater early response rate at 1–2 weeks after initiating therapy. Conclusions: While preliminary in nature, these results show an immediate and sustained proliferative response followed by a delayed metabolic response beginning after two weeks in metastatic renal cell carcinoma treated with a continuous daily dose of 37.5 mg sunitinib. The results provide evidence of tumor response to lower-dose sunitinib while also supporting the inclusion of PET imaging as a tool for early assessment in oncological clinical trials. Trial registration: ID: NCT00694096